Table 2. Demographics and baseline clinical characteristics according to the development of allograft failure.
| Allograft failure (n = 286, 9.9%) | No allograft failure (n = 2616, 90.1%) | Total (n = 2902, 100.0%) | p | ||
|---|---|---|---|---|---|
| Male gender | 190 (66.4) | 1534 (58.6) | 1724 (59.4) | 0.011 | |
| Age (years) | 41.5 (32.0, 49.3) | 42.0 (33.0, 50.8) | 42.0 (33.0, 51.0) | 0.444 | |
| Body mass index (kg/m2) | 22.7 (20.5, 24.5) | 22.0 (20.1, 24.3) | 22.1 (20.1, 24.4) | 0.042 | |
| Smoking status | Never | 220 (76.9) | 2054 (78.5) | 2274 (78.4) | <0.001 |
| Former | 18 (6.3) | 295 (11.3) | 313 (10.8) | <0.001 | |
| Current | 48 (16.8) | 267 (10.2) | 315 (10.9) | <0.001 | |
| Hypertension | 242 (84.6) | 2199 (84.1) | 2441 (84.1) | 0.807 | |
| Diabetes mellitus | 52 (18.2) | 429 (16.4) | 481 (16.6) | 0.441 | |
| Vascular disease | 26 (9.1) | 163 (6.2) | 189 (6.5) | 0.063 | |
| Cause of ESRD | GN | 50 (17.9) | 585 (23.5) | 635 (22.9) | <0.001 |
| Diabetes | 40 (14.3) | 330 (13.2) | 370 (13.3) | <0.001 | |
| Hypertension | 11 (3.9) | 189 (7.6) | 200 (7.2) | <0.001 | |
| Other | 35 (12.2) | 450 (17.2) | 485 (16.7) | <0.001 | |
| Unknown | 144 (51.4) | 938 (37.6) | 1082 (39.0) | <0.001 | |
| Era | 1997–2001 | 171 (59.8) | 601 (23.0) | 772 (26.6) | <0.001 |
| 2002–2006 | 78 (27.3) | 762 (29.1) | 840 (28.9) | <0.001 | |
| 2007–2012 | 37 (12.9) | 1253 (47.9) | 1290 (44.5) | <0.001 | |
| Age of donor (years) | 40.5 (29.0, 47.0) | 40.0 (30.0, 48.0) | 40.0 (30.0, 48.0) | 0.480 | |
| Male gender of donor | 163 (57.0) | 1500 (57.3) | 1663 (57.3) | 0.910 | |
| BMI of donor (kg/m2) | 23.2 (20.8, 25.2) | 23.4 (21.3, 25.6) | 23.4 (21.2, 25.6) | 0.177 | |
| Donor type | Living related | 122 (42.7) | 1432 (54.7) | 1554 (53.5) | <0.001 |
| Living unrelated | 79 (27.6) | 627 (24.0) | 706 (24.3) | <0.001 | |
| Deceased | 85 (29.7) | 557 (21.3) | 642 (22.1) | <0.001 | |
| HLA-DR mismatch | 0 | 43 (15.8) | 565 (22.3) | 608 (21.7) | 0.039 |
| 1 | 162 (59.6) | 1353 (53.4) | 1515 (54.0) | 0.039 | |
| 2 | 67 (24.6) | 616 (24.3) | 683 (24.3) | 0.039 | |
| HLA mismatch | 0–2 | 68 (25.0) | 815 (32.4) | 883 (31.7) | 0.040 |
| 3–4 | 143 (52.6) | 1164 (46.3) | 1307 (46.9) | 0.040 | |
| 5–6 | 61 (22.4) | 536 (21.3) | 597 (21.4) | 0.040 | |
| CNIs | Cyclosporine A | 178 (62.2) | 1165 (44.5) | 1343 (50.5) | <0.001 |
| Tacrolimus | 102 (35.7) | 1207 (46.1) | 1309 (49.3) | <0.001 | |
| Induction therapy | 77 (26.9) | 1466 (56.0) | 1543 (53.2) | <0.001 | |
| Baseline laboratory findings | |||||
| Serum albumin (mg/dL) | 3.7 (3.4, 4.1) | 3.7 (3.3, 4.1) | 3.7 (3.4, 4.1) | 0.165 | |
| Hemoglobin (g/dL) | 10.0 (8.7, 10.9) | 10.5 (9.3, 11.6) | 10.4 (9.3, 11.5) | <0.001 | |
| Serum calcium (mg/dL) | 9.0 (8.5, 9.7) | 9.1 (8.6, 9.6) | 9.1 (8.6, 9.7) | 0.339 | |
| Serum phosphorus (mg/dL) | 5.3 (4.3, 6.5) | 5.1 (4.1, 6.2) | 5.1 (4.1, 6.2) | 0.096 | |
| Serum total cholesterol (mg/dL) | 162.0 (139.0, 185.5) | 160.0 (135.0, 187.8) | 160.0 (136.0, 187.0) | 0.391 | |
| Serum glucose (mg/dL) | 104.0 (87.0, 128.8) | 107.0 (90.0, 130.0) | 106.0 (89.0, 129.0) | 0.099 | |
| Serum creatinine (mg/dL) | 9.8 (7.6, 13.0) | 8.8 (6.7, 11.2) | 8.8 (6.7, 11.4) | <0.001 | |
Data are presented as the median (25th, 75th percentiles) or as a number (percent).
BMI, body mass index; CNIs, calcineurin inhibitors; ESRD, end-stage renal disease; GN, glomerulonephritis